Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on September 3, 2021. The report details corporate governance actions taken at the Company's Annual Meeting of Stockholders held on the same date and the implementation of a previously authorized reverse stock split.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate structural changes and voting results.
Material Changes and Corporate Actions
- Reverse Stock Split: The Board approved a one-for-three reverse stock split of the Company's Common Stock. The split became effective at 12:01 am Eastern Time on September 8, 2021. Every three shares issued prior to the effective time were reclassified into one share. Fractional shares were settled in cash.
- Stockholder Vote Results: Six proposals were submitted at the Annual Meeting. Five were approved, and one was rejected:
- Approved: Election of Greg J. Divis as a Class III director.
- Approved: Ratification of Mayer Hoffman McCann P.C. as the independent registered public accounting firm.
- Rejected: Proposal to increase authorized Common Stock from 150,000,000 to 290,000,000 shares. The vote was 48,327,240.55 For vs. 14,569,030.00 Against.
- Approved: Non-binding advisory vote on executive compensation (Say-on-Pay).
- Approved: Frequency of future Say-on-Pay votes set to every 3 years.
- Approved: Discretionary authority to adjourn the meeting to solicit additional proxies.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosures regarding the reverse stock split mechanics. The new CUSIP number for the Common Stock following the split is 47010C607.
Investor Verification Checklist
- Verify the effective date of the reverse stock split (September 8, 2021) and the new CUSIP number (47010C607) for trading purposes.
- Confirm the rejection of the proposal to increase authorized shares, which may impact future capital raising flexibility.
- Review the proxy statement for detailed breakdowns of the voting results and director biographies.
- Check for cash payments in lieu of fractional shares if holding a number of shares not divisible by three.